Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Crizotinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Taxanes (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms CRISP
- 29 Oct 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 29 Oct 2019 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2023.
- 05 Jun 2018 Results (n=823) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.